ES2143553T3 - Anticuerpos anti-gp39 y sus utilizaciones. - Google Patents

Anticuerpos anti-gp39 y sus utilizaciones.

Info

Publication number
ES2143553T3
ES2143553T3 ES94926659T ES94926659T ES2143553T3 ES 2143553 T3 ES2143553 T3 ES 2143553T3 ES 94926659 T ES94926659 T ES 94926659T ES 94926659 T ES94926659 T ES 94926659T ES 2143553 T3 ES2143553 T3 ES 2143553T3
Authority
ES
Spain
Prior art keywords
antibodies
cell
fixed
monoclonal
epitop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926659T
Other languages
English (en)
Inventor
Randolph J Noelle
Teresa M Foy
Alejandro Aruffo
Jeffrey A Ledbetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Bristol Myers Squibb Pharmaceutical Research Institute
Bristol Myers Squibb Pharma Co
Original Assignee
Dartmouth College
Bristol Myers Squibb Pharmaceutical Research Institute
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2143553(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College, Bristol Myers Squibb Pharmaceutical Research Institute, Bristol Myers Squibb Pharma Co filed Critical Dartmouth College
Application granted granted Critical
Publication of ES2143553T3 publication Critical patent/ES2143553T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE EXPONEN ANTICUERPOS QUE SE FIJAN A UNA PROTEINA GP39 (TAMBIEN REFERIDA COMO LIGANDO CD40). PREFERIBLEMENTE, LOS ANTICUERPOS SON ANTICUERPOS MONOCLONALES DE UN ISOTIPO IGG1 Y SE FIJAN A LA GP39. EN UNA INCORPORACION PREFERIDA, UN ANTICUERPO DE LA INVENCION SE FIJA A UN EPITOPO RECONOCIDO POR UN ANTICUERPO MONOCLONAL 24-31, PRODUCIDO POR UN HIBRIDOMA 24-31 (ATCC NUMERO DE ACCESO...) O SE FIJA A UN EPITOPO RECONOCIDO POR UN ANTICUERPO MONOCLONAL 89-76 (ATCC NUMERO DE ACCESO...). TAMBIEN SE EXPONEN COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS ANTICUERPOS. LOS ANTICUERPOS DE LA INVENCION SON UTILES PARA INHIBIR LA PROLIFERACION Y DIFERENCIACION DE LA CELULA B, LAS RESPUESTAS DE LA CELULA T Y PARA INDUCIR LA TOLERANCIA A LA CELULA T. LAS MOLECULAS DE ACIDO NUCLEICO QUE CODIFICAN LOS ANTICUERPOS ANTIGP39, O PARTES DE LOS MISMOS, ADEMAS DE VECTORES DE EXPRESION Y CELULAS ANFITRIONES QUE INCORPORAN DICHAS MOLECULAS DE ACIDO NUCLEICO TAMBIEN SE ENCUENTRAN EN LA INVENCION.
ES94926659T 1993-09-02 1994-09-02 Anticuerpos anti-gp39 y sus utilizaciones. Expired - Lifetime ES2143553T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11625593A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists

Publications (1)

Publication Number Publication Date
ES2143553T3 true ES2143553T3 (es) 2000-05-16

Family

ID=26814047

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94926677T Expired - Lifetime ES2120067T3 (es) 1993-09-02 1994-09-02 Metodos para inducir tolerancia de celulas t antigeno especifica.
ES94926659T Expired - Lifetime ES2143553T3 (es) 1993-09-02 1994-09-02 Anticuerpos anti-gp39 y sus utilizaciones.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94926677T Expired - Lifetime ES2120067T3 (es) 1993-09-02 1994-09-02 Metodos para inducir tolerancia de celulas t antigeno especifica.

Country Status (17)

Country Link
US (5) US5747037A (es)
EP (2) EP0721346B1 (es)
JP (3) JP3007977B2 (es)
CN (2) CN1127351C (es)
AT (2) ATE188487T1 (es)
AU (2) AU696235B2 (es)
DE (2) DE69422523T2 (es)
DK (2) DK0721346T3 (es)
ES (2) ES2120067T3 (es)
FI (2) FI106306B (es)
GR (2) GR3027658T3 (es)
HU (2) HU218610B (es)
IL (1) IL110855A (es)
NO (2) NO321098B1 (es)
NZ (3) NZ273207A (es)
PT (1) PT721469E (es)
WO (2) WO1995006666A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1995006666A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JPH08239324A (ja) * 1995-03-03 1996-09-17 Fusanori Hamashima 免疫抑制剤
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
DE19634159C1 (de) * 1996-08-23 1997-09-25 Gsf Forschungszentrum Umwelt Induktion einer Tumorimmunität durch Injektion von Hybridzellen
AU4352997A (en) * 1996-08-30 1998-03-19 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
PL193966B1 (pl) * 1997-01-10 2007-04-30 Biogen Idec Ma Zastosowanie przeciwciał przeciwko CD40L lub pochodnych
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
AU2845400A (en) * 1998-12-24 2000-07-31 Phairson Medical Inc. Treatment and prevention of immune rejection reactions
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
WO2001000679A2 (en) * 1999-06-29 2001-01-04 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001066141A1 (fr) * 2000-03-06 2001-09-13 Eisai Co., Ltd. Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1286692A4 (en) * 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2001094586A2 (en) * 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002040050A1 (en) * 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Non-lethal methods for conditioning a recipient for bone marrow transplantation
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
JP3845735B2 (ja) * 2002-04-03 2006-11-15 学校法人慶應義塾 Ｃｄ４０ｌアンタゴニストを有効成分とする天疱瘡治療剤
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
DE602004029252D1 (de) * 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
JP4943161B2 (ja) * 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1851308B1 (en) * 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
CN100423775C (zh) * 2005-04-15 2008-10-08 中国农业科学院兰州兽医研究所 牛衣原体病灭活疫苗及其制备与检验方法
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP1996716B1 (en) * 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP2052848A1 (de) 2007-10-27 2009-04-29 Joint Solar Silicon GmbH & Co. KG Aufbereitung von Formlingen aus Reinstsilizium
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US8518410B2 (en) * 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
EP2396348B1 (en) * 2009-02-10 2015-04-08 The Trustees of Columbia University in the City of New York Compositions comprising hla-e for use in methods for inducing transplantation tolerance
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890297A1 (ru) 2015-07-14 2018-06-29 Иммьюнекст, Инк. Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
CA2946465C (en) 2015-11-12 2022-03-29 Delta Faucet Company Ozone generator for a faucet
US20170332610A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies
KR102142499B1 (ko) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
KR100283541B1 (ko) * 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
WO1995006666A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
EP0721346B1 (en) 1998-06-10
EP0721346A1 (en) 1996-07-17
FI960980A7 (fi) 1996-04-30
AU7644594A (en) 1995-03-22
EP0721469B1 (en) 2000-01-05
CN1149299A (zh) 1997-05-07
CN1134113A (zh) 1996-10-23
AU707110B2 (en) 1999-07-01
DE69422523T2 (de) 2000-10-12
HU218610B (hu) 2000-10-28
NO960861L (no) 1996-04-30
NO960862D0 (no) 1996-03-01
NZ273207A (en) 1997-09-22
GR3033095T3 (en) 2000-08-31
US20020187135A1 (en) 2002-12-12
US5747037A (en) 1998-05-05
EP0721469A1 (en) 1996-07-17
HUT74250A (en) 1996-11-28
DK0721469T3 (da) 2000-05-01
NZ273221A (en) 2001-09-28
JPH09502096A (ja) 1997-03-04
ATE188487T1 (de) 2000-01-15
FI960978A0 (fi) 1996-03-01
HUT74246A (en) 1996-11-28
NZ549136A (en) 2008-02-29
NO960861D0 (no) 1996-03-01
PT721469E (pt) 2000-04-28
NO321036B1 (no) 2006-03-06
GR3027658T3 (en) 1998-11-30
US20060222649A1 (en) 2006-10-05
FI960980A0 (fi) 1996-03-01
DE69411025T2 (de) 1999-01-07
CN100341896C (zh) 2007-10-10
FI106306B (fi) 2001-01-15
HU9600522D0 (en) 1996-04-29
JP3098739B2 (ja) 2000-10-16
WO1995006481A1 (en) 1995-03-09
AU696235B2 (en) 1998-09-03
AU3518397A (en) 1997-10-30
AU678532B2 (en) 1997-05-29
ES2120067T3 (es) 1998-10-16
CN1127351C (zh) 2003-11-12
AU7642994A (en) 1995-03-22
IL110855A (en) 1999-04-11
US6312692B1 (en) 2001-11-06
WO1995006666A1 (en) 1995-03-09
US5876718A (en) 1999-03-02
HU9600521D0 (en) 1996-04-29
JP3007977B2 (ja) 2000-02-14
NO321098B1 (no) 2006-03-20
NO960862L (no) 1996-04-30
ATE167062T1 (de) 1998-06-15
DE69411025D1 (de) 1998-07-16
IL110855A0 (en) 1994-11-28
JPH09502186A (ja) 1997-03-04
JP2991499B2 (ja) 1999-12-20
FI105528B (fi) 2000-09-15
US7722874B2 (en) 2010-05-25
FI960978L (fi) 1996-04-29
HU220296B (hu) 2001-11-28
DK0721346T3 (da) 1999-03-22
DE69422523D1 (de) 2000-02-10
JPH11189543A (ja) 1999-07-13

Similar Documents

Publication Publication Date Title
Binder et al. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells
Chan et al. The 65-kDa carrot microtubule-associated protein forms regularly arranged filamentous cross-bridges between microtubules
Gearhart et al. Successive switching of antibody isotypes expressed within the lines of a B-cell clone.
ES8506902A1 (es) Un procedimiento para la purificacion de un antigeno.
AR013201A1 (es) Proteina interleuquina-6 receptor interleuquina-6 quimerica soluble, analogos de la misma, una secuencia de adn, un vector de adn, celulas de mamifero transformadas incapaz de generar un animal, un metodo para producir una proteina quimerica, la utilizacion de dicha proteina para la preparacion de u
DK0576623T4 (da) Bindingsdomæner i Notch-proteiner
Song et al. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus
ATE348175T1 (de) Method eder intrazellularen bindung von zielgerichteten molekülen
SE9201331D0 (sv) Protein l och hybridproteiner daerav
ES2112865T3 (es) Anticuerpos igg purificados.
UA99701C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
Sheoran et al. Monoclonal antibodies to subclass-specific antigenic determinants on equine immunoglobulin gamma chains and their characterization
PT759942E (pt) Receptor de interleucina-15
BR9911270A (pt) Métodos e meios para expressão de polipeptìdeos de mamìferos em plantas monocotiledÈneas
Foster et al. Lipid raft proteomics: more than just detergent-resistant membranes
Moretta et al. Phenotypic characterization of human cytolytic T lymphocytes in mixed lymphocyte culture.
Manakkat Vijay et al. Cell fate dynamics and genomic programming of plasma cell precursors
Köhler et al. Cellular and molecular restrictions of the lymphocyte fusion
Schick III et al. Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
Bikoff et al. T cell recognition of endogenous IgG2a expressed in B lymphoma cells
Popović et al. Adhesins of immunoglobulin-like superfamily from earthworm Eisenia foetida
Rojas-Gutiérrez et al. Giardia intestinalis coiled-coil cytolinker protein 259 interacts with actin and tubulin
Lomonte et al. Detection of proteins antigenically related to Bothrops asper myotoxin in crotaline snake venoms
Barker et al. Identification of murine erythrocyte autoantigens and cross-reactive rat antigens
Kubota et al. DNA affinity column chromatography: application in the isolation of distinct antibody populations from SLE sera

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 721469

Country of ref document: ES